Article Text

Download PDFPDF
Preoperative Fluorine 18 Fluorodeoxyglucose Tumoral Uptake Ratio Between Upper and Lower Abdomen in Primary Advanced-Stage Ovarian Cancer
  1. Seung-Hyuk Shim, MD*,
  2. Dae-Yeon Kim, MD, PhD,
  3. Min-Jung Seo, MD,
  4. Shin-Wha Lee, MD, PhD,
  5. Jeong-Yeol Park, MD, PhD,
  6. Jong Jin Lee, MD, PhD,
  7. Jong-Hyeok Kim, MD, PhD,
  8. Yong-Man Kim, MD, PhD,
  9. Young-Tak Kim, MD, PhD and
  10. Joo-Hyun Nam, MD, PhD
  1. *Department of Obstetrics and Gynecology, School of Medicine, Konkuk University; and Departments of
  2. Obstetrics and Gynecology and
  3. Nuclear Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  1. Address correspondence and reprint requests to Dae-Yeon Kim, MD, PhD, Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, 388-1, Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea. E-mail:


Objective The objective of this study was to assess whether the ratio of upper abdomen (UA) to lower abdomen (LA) (relative to the umbilicus) standardized fluorine 18 fluorodeoxyglucose uptake, as measured by preoperative positron emission tomography and computed tomography, is predictive of recurrence, survival, and suboptimal cytoreduction (residual tumor >1.0 cm) in advanced-stage ovarian cancer (AOC).

Methods Positron emission tomography/computed tomography before surgical staging was performed in 159 AOC patients. The ratio between the highest maximum standardized uptake value (SUVmax) in the UA and the LA was expressed as UA/LA SUVmax. Clinicopathological characteristics and follow-up information were collected retrospectively. Cox proportional hazards analysis was used to identify prognostic factors for recurrence and survival. Logistic regression analysis was used to identify predictors of suboptimal cytoreduction.

Results The median age and follow-up period were 55 years (range, 27–80 years) and 32 months (range, 1–92 months), respectively; 133 and 26 patients had stage III and IV disease, respectively. There were 120 and 54 cases of recurrence and disease-specific death, respectively. Multivariate analysis showed that recurrence was associated significantly with high UA/LA SUVmax (P < 0.05; hazard ratio [HR], 4.902; 95% confidence interval [CI], 2.521–9.531) and suboptimal cytoreduction (P < 0.05; HR, 2.431; 95% CI, 1.561–3.788), and that disease-specific death was significantly associated with high UA/LA SUVmax (P < 0.05; HR, 2.777; 95% CI, 1.270–6.075), suboptimal cytoreduction (P < 0.05; HR, 1.951; 95% CI, 1.080–3.524), and histology (P < 0.05; HR, 4.134; 95% CI, 1.676–10.196). Upper abdomen/lower abdomen SUVmax was the only independent predictor of suboptimal cytoreduction (P < 0.05; odds ratio, 4.644; 95% CI, 1.676–12.862).

Conclusions High preoperative UA/LA SUVmax was significantly associated with poor prognosis and may be predictive of suboptimal cytoreduction in AOC. This parameter may be considered in the treatment of AOC patients.

  • Ovarian cancer
  • Fluorine 18 fluorodeoxyglucose
  • Positron emission tomography and computed tomography (PET/CT)
  • Prognosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (

  • The authors declare no conflicts of interest.